NCT06783166

Assessing the Clinical Outcomes of Dapagliflozin Versus Acetazolamide in Patients With Acute Heart Failure

• Status: Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Mansoura University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study investigates the comparative clinical outcomes of dapagliflozin, an SGLT-2 inhibitor, versus acetazolamide, a carbonic anhydrase inhibitor, in patients hospitalized with acute heart failure (AHF). The trial aims to assess the effectiveness of these drugs in improving natriuretic and diuretic responses and shortening hospital stays. Dapagliflozin and acetazolamide will be added to standard loop diuretic therapy, and their safety profiles will be evaluated to identify potential side effects. This research seeks to provide evidence for incorporating these drugs into AHF management, with the potential to improve clinical outcomes.

Conditions

• Acute Heart Failure

Interventions

Type	Name	Description
DRUG	Dapagliflozin 10mg	Dapagliflozin 10 mg is a medication classified as a sodium-glucose cotransporter-2 (SGLT-2) inhibitor.
DRUG	Acetazolamide 500mg	Acetazolamide 500 mg is a medication classified as a carbonic anhydrase inhibitor.

Timeline

• Start date: 2024-08-15
• Primary completion: 2025-07-01
• Completion: 2025-08-01
• First posted: 2025-01-20
• Last updated: 2025-01-20

Locations

1 site across 1 country: Egypt